Concepedia

Rachel B. Wagman

RB

45

Publications

5.7K

Citations

32

H-Index

2005

Active since

Affiliations

Amgen (United States)(Current)

University of British Columbia

Colorado Center for Bone Research

Université Laval

Columbia University

Rachel B. Wagman is an author at Amgen (United States) specializing in medicine, osteoporosis, and orthopaedics.

Top concepts

Publications per year

2005–2024

45

Publications

45

10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension

Henry G. Bone, Rachel B. Wagman, Maria Luisa Brandi et al. · The Lancet Diabetes & Endocrinology · 2017 · 916 citations · Full text

, , +9

Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial

Jacques P. Brown, Richard L. Prince, Chad Deal et al. · Journal of Bone and Mineral Research · 2008 · 595 citations

, , +16

Early Changes in Biochemical Markers of Bone Formation Predict BMD Response to Teriparatide in Postmenopausal Women With Osteoporosis

Peiqi Chen, Julie Satterwhite, Angelo A. Licata et al. · Journal of Bone and Mineral Research · 2005 · 308 citations · Full text

The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study

Socrates E. Papapoulos, Kurt Lippuner, Christian Roux et al. · Osteoporosis International · 2015 · 275 citations · Full text

Effects of denosumab on bone histomorphometry: The FREEDOM and STAND studies

Ian R. Reid, Paul D. Miller, Jacques P. Brown et al. · Journal of Bone and Mineral Research · 2010 · 249 citations · Full text

Rows per page

1–5 of 45